trending Market Intelligence /marketintelligence/en/news-insights/trending/80rHUrcbwMz27OpUaHT6ag2 content esgSubNav
In This List

Amgen's cancer therapy meets primary endpoint in phase 2 study

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Amgen's cancer therapy meets primary endpoint in phase 2 study

Amgen Inc. said the phase 2 trial of Imlygic, in combination with Bristol-Myers Squibb Co.'s Yervoy, met its main goal in an aggressive form of skin cancer.

The study showed that a higher number of unresectable advanced melanoma patients 38.8% experienced a reduction in their tumor compared to 18% for those on Yervoy alone.

Patients on the combination arm were also able to keep their disease at bay for an average of 8.2 months compared to 6.4 months in the Yervoy arm. Amgen said the effect was not statistically significant, but further analysis is pending.